{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+adalimumab", "query": { "intervention": "Placebo to match adalimumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+adalimumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T09:09:16.372Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02497469", "title": "An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Vedolizumab placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 771, "start_date": "2015-06-29", "completion_date": "2019-01-18", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 77, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497469" }, { "nct_id": "NCT05020730", "title": "Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "PTM-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phoenicis Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-05-05", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2022-10-26", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 3, "location_summary": "Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020730" }, { "nct_id": "NCT01004432", "title": "Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Arthritis, Rheumatoid", "Autoimmune Diseases" ], "interventions": [ { "name": "Golimumab 50 mg SC", "type": "DRUG" }, { "name": "Golimumab 2 mg/kg IV", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004432" }, { "nct_id": "NCT02437253", "title": "Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mucopolysaccharidosis Type I", "Mucopolysaccharidosis Type II", "Mucopolysaccharidosis Type VI" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 2, "start_date": "2015-05", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437253" }, { "nct_id": "NCT03104400", "title": "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo to Upadacitinib", "type": "DRUG" }, { "name": "Placebo to Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1705, "start_date": "2017-04-27", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 114, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104400" }, { "nct_id": "NCT06996652", "title": "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "REM Sleep Behavior Disorder" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 108, "start_date": "2026-08-17", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 18, "location_summary": "Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996652" }, { "nct_id": "NCT06972446", "title": "A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lutikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ravagalimab", "type": "DRUG" }, { "name": "ABBV-8736", "type": "DRUG" }, { "name": "ABBV-701", "type": "DRUG" }, { "name": "ABBV-848", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-06-20", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 49, "location_summary": "Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972446" }, { "nct_id": "NCT00595413", "title": "Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo matched to atacicept", "type": "DRUG" }, { "name": "Atacicept: with loading dose", "type": "DRUG" }, { "name": "Atacicept", "type": "DRUG" }, { "name": "Adalimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 311, "start_date": "2007-09", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00595413" }, { "nct_id": "NCT02065570", "title": "Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 514, "start_date": "2014-05-01", "completion_date": "2020-01-30", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065570" }, { "nct_id": "NCT03816397", "title": "Adalimumab in JIA-associated Uveitis Stopping Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Uveitis", "JIA" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Nisha Acharya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 87, "start_date": "2020-03-15", "completion_date": "2025-04-03", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-09-30T09:09:16.372Z", "location_count": 11, "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816397" } ] }